The use of historical controls in rare disease trials, using existing medical history information on a group of similar patients, rather than using a traditional placebo group, is gaining industry and regulatory support.  Will Maier discusses challenges and opportunities in the Autumn 2019 issue of Pharmafile.

Read the article

Rare and orphan diseases insights

ICON's Rare and Orphan Diseases team provides analysis including whitepapers, blogs and contributions to media and industry conversations relating to all aspects of rare and orphan diseases in clinical trials.

Read more